We previously observed that TRAIL-resistant glioma cell lines often exhibited high levels of Akt activation (Fig. 1) and, thus, we hypothesized that Akt pathway inhibition via the PI3 kinase inhibitor BKM120 could work with TRAIL to promote cell death in human glioma. This evidence concerns the gene AKT1 and central nervous system cancer.